Compare Crispr Therapeutics AG (CRSP) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Redwire Corporation — how do they compare? Crispr Therapeutics AG trades at $53.04 (market cap $4.88B), while Redwire Corporation trades at $9.48 (market cap $2.44B). The key difference: Crispr Therapeutics AG is far larger — about 2× Redwire Corporation's market cap, and Redwire Corporation is more actively traded (11,053,212 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Redwire Corporation for 18 Days on average.
| CRSP | RDW | |
|---|---|---|
Market Cap | $4.88B | $2.44B |
Volume | 2,861,747 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $74.92 | $25.90 |
52-Week Low | $44.34 | $5.06 |
Typical Hold Time | 77 Days | 18 Days |
Enterprise Value | $3.30B | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
Redwire Corporation (RDW) trades at $9.53, down 6.93% on the day, with technical indicators showing bearish momentum despite oversold RSI readings. The company reported negative earnings with Q2 2026 EPS of -$0.19 missing expectations, while revenue grew to $335.38M in 2025. Recent positive developments include a $981M Space Force contract award and partnerships with Honda and Sophia Space for robotics and orbital data centers.
Despite strong analyst support (80% buy ratings) and a $14.88 price target representing 56% upside, RDW faces significant fundamental challenges with negative profit margins and cash burn. The stock presents a high-risk opportunity for investors betting on space infrastructure growth, but requires careful monitoring of profitability improvements and execution on contract wins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
